Haematocrit, Glycosylated Haemoglobin and Diabetic Microangiopathy
Dear Sir, Poorly controlled diabetics tend to have higher HbA1 values than well-controlled diabetics and nondiabetics [1] . It has been suggested that glycosylated haemoglobin, by causing a shift in the oxygen dissociation curve [2] , may lead to local tissue hypoxia and so stimulate erythropoietin production. Ditzel and Standl [3] have suggested a role for tissue hypoxia in the evolution of microvascular diabetic complications. Not only could local hypoxia be damaging by itself, it could also, by the mechanism outlined induce polycythaemia, increase blood viscosity and so impair flow in the microcirculation.
In a recent paper Graham et al. (Diabetologia 18: 205, 1980) claimed that diabetics tend to have a relative polycythaemia which correlates with their HbA1 values when compared with non-diabetics. We would like to raise several points. First, although retinopathy and nephropathy often occur together and are therefore both considered to be examples of microangiopathy, it is not yet proven that they have an identical aetiopathogenesis. Secondly, when severe nephropathy coexists with retinopathy blood analysis may reveal a normocytic normochromic anaemia. When assessing the degree of polycythaemia we agree that red cell mass is the most accurate method currently available but we feel that as a simpler method the packed cell volume (PCV) or haematocrit is a more useful index of polycythaemia than the red cell count which was the only parameter used by Graham et al. Blood flow is partly dependent on viscosity which is directly related to the PCV [4] .
We have analysed the PCV and HbA1 values in a series of Type 1 (insulin-dependent) diabetics with and without microangiopathy divided into the following groups; Group 1 (22 patients) without any complications; Group 2 (26 patients) proliferative retinopathy without evidence of nephropathy, serum creatinine <0.10mmol/1; Group 3 (8 patients) proliferative retinopathy with biochemical evidence of early nephropathy, serum creatinine >0.10mmol/1; Group 4 (5 patients) proliferative retinopathy with overt nephropathy serum creatinine range 0.16-0.83 mmol/litre. The patients with and without complications had a similar age distribution and duration of diabetes.
There was no difference in the PCV between the patients without complications and those with proliferative retinopathy alone (Group 1: mean PCV 0.42 + 0.04; Group 2: mean PCV 0.41 _+ 0.04). In addition, there was no significant difference in haemoglobin values between the retinopathy only group (mean Hb13.7 _+ 1.6g/100ml) and the patients with nephropathy (Groups 3 + 4: mean Hb 12.8 _+ 2.1 g/100 ml) although the Hb tended to fall as renal impairment progressed (Group 3: mean Hb 13.6 _+ 1.4 g/100 ml, Group 4: mean Hb 11.6 + 2.3 g/100 ml. Similarly, there was no significant difference in the PCV values between the retinopathy only patients (Group 2) and those with nephropathy (Groups 3 + 4) although Group 4 had, as expected, the lowest mean PCV (0.35 + 0.07). When all the groups were considered together we found no correlation between PCV and HbA1 values (r=-0.18). This lack of correlation was also found in the patients without complications when considered separately. However, the patients without complications had a significantly lower mean HbA1 value than those with complications.
Our conclusion is that polycythaemia as measured by PCV or ITo does not appear evident in our series of patients with or without different combinations of microvascular complications.
Furthermore the haematocrit does not appear to be related to the glycosylated haemoglobin level. We question therefore that glycosylation of haemoglobin per se leads to an increase in haematocrit and that as a result relative polycythaemia ensues. 
Chromium and insulin Secretion
Dear Sir, In their most interesting paper Ghafghazi et al.
[1] make a valid point in stating that supplementation with chromium will only be of value in those subjects who are chromium deficient. However, the validity of their main conclusion, that chromium inhibits the secretion of insulin is open to question on several points.
Firstly, they could only demonstrate a significant effect by using levels of chromium (0.5 retool/l) which are at least 3 orders of magnitude greater than the circulating level in man [2] . Under these circumstances the fact that the response was dose dependant is irrelevant.
Secondly, the biologically active form appears to by an organic complex of the metal, and ionic chromium is converted to this form in the intact animal [3, 4] . It would seem, therefore, that the chromic chloride was not exerting a physiological effect.
Thirdly, if the animals were not chromium deficient, why should the chromic chloride have any effect?
It would be eminently desirable to repeat this experiment using other trace metals which may be 
